Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Researchers urged caution, recommending that diabetic patients on GLP-1 therapies undergo regular eye screening….

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

More than 2,000 lawsuits are now targeting the makers of Ozempic and Zepbound, with patients claiming the drugs caused dangerous and sometimes permanent health problems. The cases, consolidated in ...

Novo Nordisk, the manufacturer of Ozempic, is facing a lawsuit over alleged vision problems caused by the drug ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

The company said it was reviewing Mounjaro pricing with other governments and expected to make similar adjustments in certain ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

Novo Nordisk's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...